Abstract
The development of new antimicrobial agents for the treatment of infectious diseases remains challenging due to the increasing impact of antibiotic resistance. Since salicylanilides and esters of pyrazine-2-carboxylic acid have been described as potential antimicrobials, we have designed and synthesized a series of 2-(phenylcarbamoyl)phenyl pyrazine-2-carboxylates. These were evaluated in vitro for the activity against fungi and Gram-positive and Gram-negative bacteria. All derivatives showed significant antibacterial activity against Gram-positive strains (MIC ≥ 0.98 µmol/L) including methicillin-resistant Staphylococcus aureus. The most active molecule was 5-chloro-2-(3-chlorophenylcarbamoyl)phenyl pyrazine-2-carboxylate. With one exception these esters were at least partly active against fungi tested strains, in particular against mould strains (MIC ≥ 1.95 µmol/L). The most active antifungal agent overall proved to be 2-(4-bromophenylcarbamoyl)-4-chlorophenyl pyrazine-2-carboxylate.
Keywords: Antibacterial activity, antifungal activity, in vitro activity, pyrazine-2-carboxylic acid ester, salicylanilide, salicylanilide ester, salicylanilide, Clostridium difficile, Staphylococcus aureus, MRSA, fungal pathogens
Medicinal Chemistry
Title:In Vitro Antibacterial and Antifungal Activity of Salicylanilide Pyrazine-2- carboxylates
Volume: 8 Issue: 4
Author(s): Martin Kratky, Jarmila Vinsova and Vladimir Buchta
Affiliation:
Keywords: Antibacterial activity, antifungal activity, in vitro activity, pyrazine-2-carboxylic acid ester, salicylanilide, salicylanilide ester, salicylanilide, Clostridium difficile, Staphylococcus aureus, MRSA, fungal pathogens
Abstract: The development of new antimicrobial agents for the treatment of infectious diseases remains challenging due to the increasing impact of antibiotic resistance. Since salicylanilides and esters of pyrazine-2-carboxylic acid have been described as potential antimicrobials, we have designed and synthesized a series of 2-(phenylcarbamoyl)phenyl pyrazine-2-carboxylates. These were evaluated in vitro for the activity against fungi and Gram-positive and Gram-negative bacteria. All derivatives showed significant antibacterial activity against Gram-positive strains (MIC ≥ 0.98 µmol/L) including methicillin-resistant Staphylococcus aureus. The most active molecule was 5-chloro-2-(3-chlorophenylcarbamoyl)phenyl pyrazine-2-carboxylate. With one exception these esters were at least partly active against fungi tested strains, in particular against mould strains (MIC ≥ 1.95 µmol/L). The most active antifungal agent overall proved to be 2-(4-bromophenylcarbamoyl)-4-chlorophenyl pyrazine-2-carboxylate.
Export Options
About this article
Cite this article as:
Kratky Martin, Vinsova Jarmila and Buchta Vladimir, In Vitro Antibacterial and Antifungal Activity of Salicylanilide Pyrazine-2- carboxylates, Medicinal Chemistry 2012; 8(4) . https://dx.doi.org/10.2174/157340612801216346
DOI https://dx.doi.org/10.2174/157340612801216346 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Patent Selections
Recent Patents on Biotechnology Diversity of Bacteria and Bacterial Products as Antibiofilm and Antiquorum Sensing Drugs Against Pathogenic Bacteria
Current Drug Targets Structural Analysis of Dihydrofolate Reductase and Thymidylate Synthase from Mammalian and Pathogenic Organisms
Current Enzyme Inhibition Hodgkin Lymphoma in HIV Positive Patients
Current HIV Research Editorial (Thematic Issue: Pulmonary Delivery of Systemic Drugs- from Aerosol Generation to Efficacious Delivery)
Current Pharmaceutical Design Nanostructured Approaches for the Targeted Delivery of Antibiotics in Difficult Infections
Current Organic Chemistry Quantification of Rifaximin in Tablets by an Environmentally Friendly Visible Spectrophotometric Method
Current Pharmaceutical Analysis Can Chest Computed Tomography Findings of Symptomatic COVID-19 Patients Upon Admission Indicate Disease Prognosis and Clinical Outcome?
Current Medical Imaging Large Disclosing the Nature of Computational Tools for the Analysis of Next Generation Sequencing Data
Current Topics in Medicinal Chemistry Synthesis and Antimycobacterial Evaluation of N-(E)-heteroaromaticpyrazine-2-carbohydrazide Derivatives
Medicinal Chemistry Editorial [ The Medicinal Chemistry of Anti-Infectious Agents Guest Editor: Concepcion Gonzalez-Bello ]
Current Topics in Medicinal Chemistry Co-Crystals for Generic Pharmaceuticals: An Outlook on Solid Oral Dosage Formulations
Recent Advances in Drug Delivery and Formulation Recent Advances in Clinical Immunology, Endocrine & Metabolic Drugs: An Editorial Overview
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Gender Disparity in Pediatric Diseases
Current Molecular Medicine Biologic Agents for Treatment of Rheumatoid Arthritis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Adherence to Antiretroviral Therapy Among Iranian HIV/AIDS Patients
Current Clinical Pharmacology Editorial [Hot topic: Structural Genomics (Executive Editor: Yu Wai Chen)]
Infectious Disorders - Drug Targets In Vitro Antimycobacterial Activity of New 7-Chloroquinoline Derivatives
Letters in Drug Design & Discovery Environmental Factors Contributing to Susceptibility to Tuberculosis
Current Respiratory Medicine Reviews Advances in Bacterial Methionine Aminopeptidase Inhibition
Current Topics in Medicinal Chemistry